30 likes | 167 Views
2014 UK National Lipoprotein Apheresis Conference 7 th March 2014, 09:00-1600 Venue: Hilton Manchester Airport Hotel, Manchester Airport, Outwood Lane, Manchester, M90 4WP CPD accreditation: 5 CPD applied for. 0920-0930 Welcome: Dr Handrean Soran Session 1
E N D
2014 UK National Lipoprotein Apheresis Conference 7th March 2014, 09:00-1600 Venue: Hilton Manchester Airport Hotel, Manchester Airport, Outwood Lane, Manchester, M90 4WP CPD accreditation: 5 CPD applied for
0920-0930 Welcome: Dr Handrean Soran Session 1 0930-1010 Underestimation of the importance of LDL-cholesterol lowering in cardiovascular disease prevention in current practice. Professor Paul Durrington, Professor of Medicine, University of Manchester, UK. 1010-1050 Lipoprotein (a) as a cardiovascular risk factor: review of evidence and therapeutic options. Dr Dermot Neely, Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle, UK. 1050-1120 Coffee and networking Session 2 1120-1200 HoFH; is it just double trouble? The role of the LDL-receptor in lipid metabolism and implications for therapeutic options. Dr Michael France, Consultant Chemical Pathologist, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 1200-1240 Lipoprotein Apheresis: who and how should we treat? Dr Dev Datta, University Hospital Cardiff, Cardiff, UK. 1240-1350 Lunch Session 3 1350-1430 Lomitapide as a therapeutic option for HoFH. Professor Claudia Stefanutti, Professor of Internal Medicine, Extracorporeal Therapeutic Techniques Unit - Lipid Clinic and Atherosclerosis Prevention Centre, Department of Molecular Medicine ‘Sapienza’ University of Rome, Italy 1430-1500 Future therapeutic options for patients with HoFH. Dr Handrean Soran, Consultant Physician and Endocrinologist, Central Manchester University Hospital, UK. 1500-1530 Managing HoFH in children; challenges and options. Dr Andrew Morris, Consultant Paediatrician, Central Manchester University Hospitals NHS Foundation Trust. 1530-1600 Case discussions. HoFH in children; pheresis as a therapeutic option. 1600 Close Sponsors Aegereon, AMGEN, AstraZeneca, Link Medical, Sanofi. Agenda University of Manchester The Centre for Endocrinology & Diabetes
ATTENDANCE FORM 2014 UK National Lipoprotein Apheresis Conference 7th March 2014, 09:30-1600 Manchester CPD accreditation: 5 CPD applied for YES, I am able to attend the meeting on Tuesday 7th March 2014 To reserve your place, please complete the form and return at your earliest convenience to Sister Ruth Eatough Email: Ruth.Eatough@cmft.nhs.uk Fax: 0161 276 4684 CORRESPONDENCE DETAILS Name: ……………………………………………………………………………………………………………………... GP Surgery/Hospital: .…….…………………………………………………………………………………………. Role/Position:…………………………………………………………………………………………………………… Address: ………………………………………………………………………………………………………………….. ……………………………………………………………………………………………………………………………….. ……………………………………………………………………………………………………………………………….. Postcode: ……………………………………………………………………………....................................... Contact Number: ……………………………………………………………………................................... Email Address: ………………………………………………………………………………………………………… Please state any dietary requirements: ……………………………………………………………………. Signature: ……………………………………………………………………………………………………………….. Date: …………………………………………………………………………………………………………………………